X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hematology (12) 12
humans (12) 12
index medicus (10) 10
male (10) 10
middle aged (10) 10
oncology (10) 10
aged (9) 9
female (9) 9
adult (7) 7
chronic myeloid leukemia (7) 7
leukemia (7) 7
treatment outcome (7) 7
aged, 80 and over (6) 6
retrospective studies (6) 6
follow-up studies (5) 5
imatinib (5) 5
cml (4) 4
disease (4) 4
medicine & public health (4) 4
protein kinase inhibitors - therapeutic use (4) 4
therapy (4) 4
young adult (4) 4
antineoplastic agents - therapeutic use (3) 3
breccia (3) 3
care and treatment (3) 3
clinical trials (3) 3
drug administration schedule (3) 3
incidence (3) 3
italy - epidemiology (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - complications (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (3) 3
myeloid leukemia (3) 3
prevention (3) 3
prognosis (3) 3
recommendations (3) 3
review (3) 3
risk factors (3) 3
survival analysis (3) 3
adolescent (2) 2
analysis (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
bcr-abl1 (2) 2
cardiovascular diseases - epidemiology (2) 2
cardiovascular diseases - etiology (2) 2
chemotherapy (2) 2
complications (2) 2
diseases of the blood and blood-forming organs (2) 2
efficacy (2) 2
hydroxyurea (2) 2
hypertension (2) 2
imatinib mesylate - therapeutic use (2) 2
leukemia, myeloid, chronic-phase - diagnosis (2) 2
leukemia, myeloid, chronic-phase - drug therapy (2) 2
leukemia, myeloid, chronic-phase - mortality (2) 2
management (2) 2
multiple myeloma - drug therapy (2) 2
multiple-myeloma (2) 2
myeloma (2) 2
osteolytic lesions (2) 2
platelet aggregation inhibitors - therapeutic use (2) 2
ponatinib (2) 2
protein kinase inhibitors - adverse effects (2) 2
radiotherapy (2) 2
recurrence (2) 2
remission induction (2) 2
residual disease (2) 2
safety (2) 2
solitary plasmacytoma (2) 2
time factors (2) 2
toxicity (2) 2
tyrosine (2) 2
working groups (2) 2
adequate pbsc collection (1) 1
adverse events (1) 1
age (1) 1
anagrelide (1) 1
anemia (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibodies, monoclonal - therapeutic use (1) 1
anticoagulants - therapeutic use (1) 1
antimetabolites, antineoplastic - therapeutic use (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - pharmacokinetics (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
ap24534 (1) 1
apheresis harvest (1) 1
arrhythmia (1) 1
arterial occlusive diseases - epidemiology (1) 1
arterial occlusive diseases - etiology (1) 1
arterial occlusive diseases - prevention & control (1) 1
arterial occlusive event (1) 1
aspirin (1) 1
aspirin - therapeutic use (1) 1
autologous transplantation (1) 1
available therapy (1) 1
azacitidine (1) 1
azacitidine - therapeutic use (1) 1
bcr-abl (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Mediterranean journal of hematology and infectious diseases, ISSN 2035-3006, 2017, Volume 9, Issue 1, pp. e2017052 - e2017052
Solitary plasmacytoma is a rare disease characterized by a localized proliferation of neoplastic monoclonal plasma cells, without evidence of systemic disease.... 
solitary plasmacytoma | radiotherapy | ostolytic lesions | myeloma
Journal Article
Annals of Hematology, ISSN 0939-5555, 10/2018, Volume 97, Issue 10, pp. 1803 - 1808
We investigated the median estimated glomerular filtration rate (eGFR) changes in chronic myeloid leukemia (CML) patients treated front line with tyrosine... 
Cardiovascular events | Oncology | Chronic myeloid leukemia | Medicine & Public Health | Hematology | Estimated glomerular filtration | CHAIN | KINASE | GROWTH-FACTOR | HEMATOLOGY | TUBULAR REGENERATION | Follow-Up Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Dasatinib - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Imatinib Mesylate - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Young Adult | Glomerular Filtration Rate - drug effects | Imatinib Mesylate - therapeutic use | Antineoplastic Agents - adverse effects | Biotransformation | Imatinib Mesylate - adverse effects | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Adult | Female | Renal Insufficiency, Chronic - diagnosis | Antineoplastic Agents - pharmacokinetics | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications | Retrospective Studies | Myocardial Ischemia - epidemiology | Protein Kinase Inhibitors - pharmacokinetics | Cardiovascular Diseases - etiology | Kidney Tubules - drug effects | Dasatinib - therapeutic use | Renal Insufficiency, Chronic - physiopathology | Myocardial Ischemia - etiology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Pyrimidines - adverse effects | Creatinine - blood | Pyrimidines - pharmacokinetics | Aged | Dasatinib - adverse effects | Renal Insufficiency, Chronic - chemically induced | Health risk assessment | Leukemia | Index Medicus
Journal Article
Journal Article
Annals of Hematology, ISSN 0939-5555, 8/2019, Volume 98, Issue 8, pp. 1891 - 1904
Journal Article
Annals of Hematology, ISSN 0939-5555, 8/2019, Volume 98, Issue 8, pp. 1933 - 1936
Journal Article
Hematological Oncology, ISSN 0278-0232, 08/2019, Volume 37, Issue 3, pp. 296 - 302
Journal Article
Mediterranean Journal of Hematology and Infectious Diseases, 2017, Volume 9, Issue 1
Solitary plasmacytoma is a rare disease characterized by a localized proliferation of neoplastic monoclonal plasma cells, without evidence of systemic disease.... 
Myeloma | Radiotherapy | Solitary Plasmacytoma | Osteolytic Lesions | MULTIPLE-MYELOMA | UNITED-STATES | INFECTIOUS DISEASES | MANAGEMENT | EXTRAMEDULLARY PLASMACYTOMA | PROGNOSTIC-FACTORS | LIGHT-CHAIN | CLINICAL-FEATURES | FLOW-CYTOMETRY | HEMATOLOGY | BONE PLASMACYTOMAS
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 08/2019, Volume 288, pp. 124 - 127
Journal Article
Oncology Research and Treatment, ISSN 2296-5270, 12/2019, Volume 42, Issue 12, pp. 660 - 664
Background: In elderly patients with chronic myeloid leukemia (CML) responsive to imatinib, the incidence of clinically significant (CS) late chronic anemia is... 
Research Article | MESYLATE | Imatinib | IMPACT | CML | THERAPY | Late toxicity | ONCOLOGY | Anemia | RECOMMENDATIONS | Chronic myeloid leukemia | Elderly | AGE
Journal Article
Blood Reviews, ISSN 0268-960X, 03/2020, p. 100689
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5518 - 5518
Abstract Background. 5-Azacitidine (5-AZA) had changed the therapeutic approach to intermediate-2/high IPSS risk myelodysplastic syndromes (MDS) improving the... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1741 - 1741
Abstract Background. Imatinib, the first BCR/ABL kinase inhibitor, has drastically changed the chronic myeloid leukemia (CML) scenario improving the rate of... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 3845 - 3845
Introduction APL in the elderly is rare and about 5% of patients with APL are older than 70 years at diagnosis; compared to young adults, prognosis of older... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1746 - 1746
Abstract Current treatment with Tyrosine-Kinase Inhibitors (TKI) has profoundly changed long-term prognosis of newly diagnosed Chronic Myeloid Leukemia (CML).... 
Journal Article
American journal of therapeutics, ISSN 1075-2765, 02/2020, p. 1
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 4408 - 4408
Abstract Abstract 4408 PNH is a hemolytic disorder resulting from dysregulation of complement on the rbc, and is associated with immune mediated marrow failure... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.